U.S. NUCLEAR REGULATORY COMMISSION

Amendment No. 45

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below. 0212-0 5768/5

Licensee	In accordance with letters dated **January 17, 2012, and April 1, 2012,**
1. Kirksville Missouri Hospital Company, LLC d/b/a Northeast Regional Medical Center, Inc. 2. 800 West Jefferson Kirksville, MO 63501	3. License number 24-05245-01 is amended in its entirety to read as follows: 4. Expiration date March 31, 2021 5. Docket No. 030-02332 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. As needed (not to exceed 1 curie of I-131)
D. Any byproduct material permitted by 10 CFR 31.11	**D.** Prepackaged Kits	**D.** 3 millicuries
E. Gadolinium-153	**E.** Sealed sources (Isotopes Products labs, Model NES 8497)	**E.** 4 sources not to exceed 300 millicuries each

9. Authorized Use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.

B. Any imaging and localization study permitted by 10 CFR 35.200.

C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

D. In vitro studies.

E. For use in a Philips Medical Systems ADAC Laboratories attenuation Correction Device model CardioMD-AC.

CONDITIONS

10. Location of Use: 800 West Jefferson, Kirksville, Missouri.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
24-05245-01

Docket or Reference Number
030-02332

Amendment No. 45

11. Radiation Safety Officer: **Rusty Beeler, RT(R)**

12. Licensed material is only authorized for use by, or under the supervision of:

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

B. The following individuals are authorized users for medical use as indicated:

Authorized Users	Material and Use
Paul M. Williams, D.O.	10 CFR 35.100, 35.200, 35.300, Gadolinium-153 and 31.11.
Frederick J. Laufer, M.D.	**10 CFR 35.100 and 35.200.**
Maria Del Pilar Duque, M.D.	**10 CFR 35.100 and 35.200.**
Beartix Araiza, M.D.	**10 CFR 35.100 and 35.200.**
Brian Ewy, D.O.	**10 CFR 35.100 and 35.200.**
Richard Bruce Karsh, M.D.	**10 CFR 35.100 and 35.200.**
Bryson Borg, M.D.	**10 CFR 35.100 and 35.200.**
Thaddeus D. Houston, M.D.	**10 CFR 35.100 and 35.200.**
Theresa Witt Tilton, M.D.	**10 CFR 35.100 and 35.200.**
Peter M. Fitzer, M.D.	**10 CFR 35.100 and 35.200.**
Ranjiv K. Saini, M.D.	**10 CFR 35.100 and 35.200.**
Richard R. Black, D.O.	**10 CFR 35.100 and 35.200.**
Jonas Singer, M.D.	**10 CFR 35.100 and 35.200.**
Jennifer Ruth Cranny, M.D.	**10 CFR 35.100, 35.200, and 35.300, limited to oral administration of sodium I-131.**

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
24-05245-01

Docket or Reference Number
030-02332

Amendment No. 45

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

16. For sealed sources not associated with 10 CFR Part 35 use, the following conditions apply:

    A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State.

    B. In the absence of a certificate from a transferor indicating that a leak test has been made within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.

    C. Sealed sources need not be tested if they contain not more than 100 microcuries of beta- and/or gamma-emitting material or not more than 10 microcuries of alpha-emitting material.

    D. Sealed sources need not be tested if they are in storage and are not being used; however, when they are removed from storage for use or transferred to another person and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

    E. The leak test shall be capable of detecting the presence of 0.005 microcurie (185 becquerels) of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie (185 becquerels) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.

    F. Tests for leakage and/or contamination, including leak test sample collection and analysis, shall be performed by the licensee or by other persons specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services.

    H. Records of leak tests results shall be kept in units of microcuries and shall be maintained for 3 years.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
24-05245-01

Docket or Reference Number
030-02332

Amendment No. 45

17. The licensee shall conduct a physical inventory every six months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all sources and/or devices received and possessed under the license. The licensee shall maintain records of the inventory of sealed sources and retain each record for 3 years after it is made. The record must include the date of the inventory, name of the individual conducting the inventory, radionuclide, number of becquerels (curies), location of sealed source, and manufacturer, model, and serial number of each sealed source, as appropriate.

18. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Letter dated October 22, 2010.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date MAY 0 3 2012

By _____
Toye L. Simmons
Materials Licensing Branch
Region III